TocilizuMab manufacturers
- Tocilizumab
-
- $0.00 / 1g
-
2024-11-14
- CAS:375823-41-9
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100G
- TocilizuMab
-
- $0.00 / 1g
-
2024-09-25
- CAS:375823-41-9
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 50kg
- TocilizuMab
-
- $10.00 / 1KG
-
2021-11-20
- CAS:375823-41-9
- Min. Order: 100KG
- Purity: 99%
- Supply Ability: 100 mt
|
| | TocilizuMab Basic information |
| Product Name: | TocilizuMab | | Synonyms: | TocilizuMab;Actemra 200;R 1569;RoActemra;Tocilizumab,Atlizumab;anti-IL-6R Tocilizumab;Tocilizumab (anti-IL-6R);Tocilizumab-Actemra | | CAS: | 375823-41-9 | | MF: | C14H12O3 | | MW: | 0 | | EINECS: | 248-451-4 | | Product Categories: | API | | Mol File: | Mol File | ![TocilizuMab Structure]() |
| | TocilizuMab Chemical Properties |
| storage temp. | Store at -80°C | | solubility | Soluble in DMSO | | form | Liquid | | color | Colorless to light yellow |
| | TocilizuMab Usage And Synthesis |
| Clinical Use | Interleukin inhibitor:
Treatment of rheumatoid arthritis in combination with methotrexate | | Drug interactions | Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant administration | | Metabolism | Tocilizumab undergoes biphasic elimination from the circulation. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear and non-linear clearance. The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations. Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance. |
| | TocilizuMab Preparation Products And Raw materials |
|